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PURPOSE. Pathologic angiogenesis is a component of many diseases, including neovascular age-
related macular degeneration, proliferation diabetic retinopathy, as well as tumor growth and
metastasis. The purpose of this project was to examine whether the system of adeno-
associated viral (AAV)–mediated CRISPR (clustered regularly interspaced short palindromic
repeats)–associated endonuclease (Cas)9 can be used to deplete expression of VEGF receptor
2 (VEGFR2) in human vascular endothelial cells in vitro and thus suppress its downstream
signaling events.
METHODS. The dual AAV system of CRISPR/Cas9 from Streptococcus pyogenes (AAV-SpGuide
and -SpCas9) was adapted to edit genomic VEGFR2 in primary human retinal microvascular
endothelial cells (HRECs). In this system, the endothelial-specific promoter for intercellular
adhesion molecule 2 (ICAM2) was cloned into the dual AAV vectors of SpGuide and SpCas9
for driving expression of green fluorescence protein (GFP) and SpCas9, respectively. These
two AAV vectors were applied to production of recombinant AAV serotype 5 (rAAV5), which
were used to infect HRECs for depletion of VEGFR2. Protein expression was determined by
Western blot; and cell proliferation, migration, as well as tube formation were examined.
RESULTS. AAV5 effectively infected vascular endothelial cells (ECs) and retinal pigment
epithelial (RPE) cells; the ICAM2 promoter drove expression of GFP and SpCas9 in HRECs,
but not in RPE cells. The results showed that the rAAV5-CRISPR/Cas9 depleted VEGFR2 by
80% and completely blocked VEGF-induced activation of Akt, and proliferation, migration as
well as tube formation of HRECs.
CONCLUSIONS. AAV-CRISRP/Cas9–mediated depletion of VEGFR2 is a potential therapeutic
strategy for pathologic angiogenesis.
Keywords: AAV5, CRISPR/Cas9, VEGFR2, angiogenesis
Vascular endothelial growth factor (VEGF) plays an essentialrole in angiogenesis, the process by which new blood
vessels grow from preexisting vessels.1 Among the VEGF
receptors 1, 2, and 3 (VEGFR1, VEGFR2, and VEGFR3),
VEGFR2 mediates nearly all the known VEGF-induced angio-
genesis effect, including microvascular permeability and
neovascularization.2,3 However, other receptors such as neuro-
pilin/semaphorin on endothelial cell surfaces also affect
angiogenesis. Neuropilin-1 can mediate vascular permeability
independently of VEGFR2 activation4 and semaphorin signaling
can also influence angiogenesis.5 Angiogenesis is critical for
supporting the rapid growth of solid tumors beyond 1 to 2 mm3
and for tumor metastasis.6 Abnormal angiogenesis is also
associated with a variety of other human diseases such as
arthritis, proliferative diabetic retinopathy (PDR), and wet age-
related macular degeneration (AMD).7
Adeno-associated viruses (AAVs) are small viruses that are
not currently known to cause any disease, and AAV-derived
vectors show promise in human gene therapy, especially for
eye disease.8,9 AAV-mediated gene therapy has been reported to
be both safe and effective in the treatment of a monogenic
disorder like Leber’s congenital amaurosis type 2.10 The
clustered regularly interspersed palindromic repeats
(CRISPR)–associated DNA endonuclease (Cas)9 in Streptococ-
cus pyogenes (SpCas9) processes pre–CRISPR RNA (pre-crRNA)
transcribed from the repeat spacers into crRNA and cleaves
invading nucleic acids on the direction of crRNA and trans-
activating crRNA (tracrRNA). A single-guide RNA (sgRNA)
engineered as a crRNA–tracrRNA chimeric RNA can direct
sequence-specific SpCas9 cleavage of double-stranded DNA
containing an adjacent ‘‘NGG’’ protospacer-adjacent motif
(PAM).11–13
The CRISPR/Cas9 system is a powerful tool for the easy and
highly specific targeting of eukaryotic genomes,14 particularly
human cells,15 and subsequent gene insertion and deletion,
resulting in reading frame shifts and protein depletion.16
Importantly, the CRISPR-Cas9 system is superior to other gene
manipulation tools in terms of reduced off-target effects.17,18
Copyright 2017 The Authors
iovs.arvojournals.org j ISSN: 1552-5783 6082
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
We have previously used a lentiviral vector to deliver the
CRISPR-Cas9 to human retinal microvascular endothelial cells
(HRECs) for depletion of VEGFR2.13 Here, we used a dual AAV
vector system to deliver CRISPR/Cas9 for depletion of VEGFR2
in HRECs and found that AAV5-CRISPR/Cas9–mediated deple-
tion of VEGFR2 was able to block VEGF-induced activation of
Akt and proliferation, migration, as well as tube formation of
HRECs.
MATERIAL AND METHODS
Major Reagents
VEGF was purchased from R&D Systems (Minneapolis, MN,
USA). Antibodies against VEGFR2, Akt, and p-Akt (S473) were
purchased from Cell Signaling Technology (Danvers, MA, USA).
The primary antibody against b-actin and secondary antibodies
of the horseradish peroxidase (HRP)–conjugated goat anti-
rabbit IgG and anti-mouse IgG were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Enhanced chemilumi-
nescent substrate for detection of HRP was purchased from
Thermo Fisher Scientific (Waltham, MA, USA).
DNA Constructs
The four 20-nt target DNA sequences preceding a 50-NGG PAM
sequence at exon 18 in the genomic VEGFR2 locus
(NC_000071.6) were selected for generating sgRNA for SpCas9
targets using the CRISPR design Web site (http://crispr.mit.edu;
in the public domain).13,19 The four target sequences were 50-
TCAGTTCCCCTTCATTGGCC-3 0 (K7), 5 0-AGGCTACTTGTC
TATTGTCA-30 (K8), 50-TTCATCTGGATCCATGACGA -30 (K9),
and 5 0-GGATCCAGATGAACTCCCAT-3 0 (K10). The control
sgRNA sequence (5 0-TGCGAATACGCCCACGCGATGGG-3 0)
was designed to target the lacZ gene from Escherichia
coli.13,19,20 The lenti-crispr v2 vector (52961)19 z, and the dual
AAV vectors (AAV-SpCas9: 60957 and AAV-SpGuide: 60958)
were purchased from Addgene (Cambridge, MA, USA).13,20
To select the most efficient sgRNA among the four sgRNAs,
the top oligos 50-CACCG-20nt (target VEGFR2 DNA sequences
K7, K8, K9, K10 or the lacZ sgRNA sequence) and bottom
oligos 50-CAAC-20 nt (20nt: complementary target VEGFR2
DNA sequences or lacZ sgRNA sequence) -C-30 were annealed
and cloned into the lenti-CRISPR v2 vector by BsmB1,
respectively.
The pAAV-U6-sgRNA-pICAM2-GFP vector originated from
AAV-SpGuide (Cat. 60958; Addgene)20 by replacing the hSyn
with the PCR-amplified promoter of intercellular adhesion
molecule 2 (ICAM2) from genomic DNA of HRECs, using Xbal/
SalI as described previously.21 The PCR primers are P1F
(forward), 50 XbaI-KpnI-ApaI-BamHI-20nt- (50-CGTCTAGAGG
GTACCGGG GCCCGGGATCCTAGA ACGA GCTGGTGC
ACGTGGC-3 0); and P1R (reverse), 5 0 SalI-AgeI-20nt- (5 0-
GGGTCGACgACCGGTCCAAGGGCTGCCTGGAGGGAG-3 0).
The pAAV-pICAM2-SpCas9 was derived from AAV-SpCas9 (Cat.
60957; Addgene) by replacing the pMecp2 with pICAM2, using
XbaI/AgeI. The DNA fragments of this ICAM2 (top: 5 0-
CTAGAgGGTACCgGGATCC TAGAACGAGCTGGTGCACG
TGGCTTCCCAA AGATCTCTCAGATAATGAGAGGAAATGC
AGTCATCAGTTTGCAGAAGGCT AGGGATTCTGGGCCATA
GCTCAGACCTGCGCCCACCATCTCC CTCC AGGCAGC
CCTTGGACCGGTgG-30; bottom: 50-TCGACcACCGGTCCAAGG
GCTGCCTG GAGGGAGATGGTGGGCGCAGGTCTGAGCTAT
GGCCCAGAATC CCTAGCCTTCTGCAAACTGATGACTGC
ATTTCCTCTCATTATCTGAGAGATCTTTGGGAAGCCACGTGC
ACCAGCTCGTTCTAGGATCCcGGTACCcT) in this vector
were synthesized by Integrated DNA Technologies (Coralville,
IA, USA).
To express SpGuides in the targeted cells, the top oligos 50-
ACCG-K7-30 and bottom oligos 50-AAC-20nt (20nt: complemen-
tary target K7 VEGFR2 DNA sequences or lacZ sgRNA
sequence) -C-3 0 were annealed and cloned into AAV-U6-
sgRNA-pICAM2-CMV vector, respectively, by SapI (New
England Biolabs, Boston, MA, USA).20 All clones were
confirmed by DNA sequencing with a primer 50-GGACTATCA
TATGCTTACCG-3 0 derived from U6 promoter that drives
expression of sgRNAs. All primers and oligos were synthesized,
and PCR products and clones were sequenced for confirmation
at the Massachusetts General Hospital DNA Core Facility
(Cambridge, MA, USA).
Cell Culture and Transfection
ARPE-19 cells (American Type Culture Collection, Manassas,
VA, USA) were cultured in a 1:1 mixture of Dulbecco’s
modified Eagle’s medium and Ham’s F-12 Nutrient Mixture
(Thermo Fisher Scientific, Grand Island, NY, USA) with 10%
inactivated fetal bovine serum (FBS; Lonza, Walkersville, MD).
Primary HRECs were purchased from Cell Systems (Kirkland,
WA, USA) and cultured in an endothelial growth medium
(EGM)-2 kit (Lonza).13 All cells were cultured at 378C in a
humidified 5% CO2 atmosphere.
22 AAV serotype 5 (AAV5) of
AAV-SpGuide and -SpCas9 were produced and the titers of
AAV5 were determined by real-time PCR by Gene Transfer
Vector Core at Schepens Eye Research Institute of Massachu-
setts Eye and Ear.
Production of Lentivirus
The lentiCRISPR v2 vector inserted with sgRNA (K7, K8, K9, or
K10) (2000 ng), the packaging plasmid psPAX2 (12260;
Addgene) (900 ng), and the envelope plasmid VSV-G (8454;
Addgene) (100 ng) were mixed together with P3000 (Thermo
Fisher Scientific) and then added to a mixture of lipofectamine
3000 (Thermo Fisher Scientific) 6 lL with OPTI-MEM (Thermo
Fisher Scientific) 90 lL. This transfection mix was incubated at
room temperature for 30 minutes and then carefully trans-
ferred into a 60-mm cell culture dish with human embryonic
kidney 293T cells that were approximately 70% confluent
without antibiotics. After 18 hours (378C, 5% CO2), the
medium was replaced with growth medium supplemented
with 30% FBS, and at 24 hours after the medium change,
lentiviruses were harvested. The viral harvest was repeated at
24-hour intervals three times. The virus-containing media were
pooled, centrifuged at 800g for 5 minutes, and the supernatant
was used to infect porcine aortic endothelial cells (PAECs)
overexpressing VEGFR2 (PAEC-KDR), supplemented with 8
lg/mL polybrene (Sigma-Aldrich Corp., St. Louis, MO, USA).
The infected cells were selected in media by using puromycin
(Sigma-Aldrich Corp.) (0.5 lg/mL) and the resulting cells were
examined by Western blot.19,22–24
Western Blot Analysis
PAEC-KDR infected with the lentivirus or HRECs with AAV5-
SpGuide and -SpCas9 (7.53 109 GC/well in 24-well plates) for
3 days at 90% confluence in a 24-well plate deprived of serum
and growth factors overnight were treated for 30 minutes with
VEGF (20 ng/mL). After rinsing twice with ice-cold phosphate-
buffered saline (PBS), cells were lysed in 13 sample buffer that
was diluted with extraction buffer (10 mM Tris-HCl, pH 7.4, 5
mM EDTA, 50 mM NaCl, 50 mM NaF, 1% Triton X-100, 20 lg/
mL aprotinin, 2 mM Na3VO4, and 1 mM phenylmethylsulfonyl
fluoride) from the 53protein sample buffer (25 mM EDTA [pH
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7.0], 10% sodium dodecyl sulfate (SDS) (Sigma-Aldrich Corp.),
500 mM dithiothreitol, 50% sucrose, 500 mM Tris HCl [pH 6.8],
and 0.5% bromophenol blue). After boiling for 5 minutes, the
samples were centrifuged for 5 minutes at 13,000g. Proteins in
the samples were separated by 10% SDS- PAGE, transferred to
polyvinylidene difluoride membranes, and subjected to West-
ern blot analyses.22 Experiments were repeated at least three
times. Signal intensity was determined by densitometry with
ImageJ software (http://imagej.nih.gov/ij/; provided in the
public domain by the National Institutes of Health, Bethesda,
MD, USA).22
Sanger DNA Sequencing
Genomic DNA was extracted from the transduced cells with
the QuickExtract DNA Extraction Solution (Epicenter, Chicago,
IL, USA) by following the manufacturer’s protocol. The
genomic fragment approximately 200 bp around the PAM
was PCR amplified with high-fidelity Herculase II DNA
polymerases (Agilent Technologies, Santa Clara, CA, USA).
The PCR primers were P10F (50-AATGCACCTAGCTTCAGCCG-
30) and P10R (50-AGCACACAAAACAACAGCCAA-3 0). The PCR
products were separated in 2% agarose gel and purified with a
gel extraction kit (Thermo Fisher Scientific) for Sanger DNA
sequencing and next generation sequencing (NGS).13
NGS Analysis of Potential Off-targets
To find potential off-targets for the K7-targeted genes, the
‘‘CRISPR Design Tool’’ (http://crispr.mit.edu/; in the public
domain) was used,20 indicating that the most potential off-
target sequence was ACAATTCCACTCCATTGGCCAAG,
which was located at chr18:-9326920. From this information,
we designed PCR primers (forward primer P30F: AGTAGT
GAAAGGCCAGTGCAA; reverse primer P30R: ACACAGGGTT
ACCACAAACCT) for PCR amplification of the DNA fragment
covering the potential K7 off-targets for Sanger DNA
sequencing and PCR primers (forward primer P31F:
GGGTTTAAAGAGTGAGTAGAA; reverse primer P31R:
GGTTACCACAAACCTTCAATT) for NGS. The PCR products
from HRECs transduced by the dual AAV-CRISPR/Cas9 vectors
either containing lacZ-sgRNA or VEGFR2-sgRNA K7 were sent
for Sanger DNA sequencing and next generation sequencing
(NGS).13
Cell Proliferation Assay
The infected HRECs were cultured into 24-well plates at a
density of 30,000 cells/well in an EGM kit. After attachment,
the cells were starved for growth factors for 7 hours. Then
VEGF (20 ng/mL) was added into the wells. The treatment was
repeated daily. After 48 hours, the cells were trypsin detached
and then counted in a hemocytometer under a light
microscope.19,22,25
Wound-Healing Assay
The wound-healing migration assay was performed as de-
scribed previously.19,26 Briefly, when the infected HRECs
reached 80% confluence in 48-well plates, they were starved
for growth factors for 8 hours, and the wells were scraped with
a sterile pipette tip (200 lL). The cells were then washed twice
to remove detached cells and treated with VEGF (20 ng/mL).
The wound was photographed at 0 and 18 hours post
wounding under a microcopy. Quantification was done by
measuring the number of pixels in the wound area, using
Adobe Photoshop (Adobe Systems, San Jose, CA, USA) and
analyzed by using ImageJ software.19,25
Tube Formation Assay
This assay was performed as described previously.19,27–29
Briefly, Cultrex Basement Extract (BME) (Trevigen, Gaithers-
burg, MD, USA) from storage at 808C was thawed overnight
on ice. Then a 96-well plate was placed on ice for at least 10 to
15 minutes, and the solution of BME (80 lL) was transferred
into each well. This plate was subsequently incubated at 378C
for 30 to 60 minutes to polymerize the gel. After 1 hour, HRECs
infected with AAV5-SpCas9 together with AAV5-SpGuide
(VEGFR2-sgRNA or lacZ-sgRNA) at a density of 2 3 104/well
in 100 lL culture medium were plated on top of each
polymerized BME gel. Specifically, the culture medium was
EBM supplemented with 0.5% horse serum and 0.1% bovine
brain extract supplemented with or without VEGF (20 ng/mL).
Images of the tubes were photographed at 6 hours post assay
under a light microscope. The data were imported as a TIFF file
into ImageJ software for calculating the total length of all
tubing with each field, using angiogenesis analysis module. The
data of three independent experiments were analyzed with
Prism 6 software (GraphPad Software, Inc., La Jolla, CA, USA).
For statistical analysis, data from the three independent
experiments were analyzed by using an unpaired t-test in Prism
6 software. P values of less than 0.05 were considered
statistically significant.
RESULTS
Establishment of Dual AAV Vectors for Delivering
CRISPR/Cas9
Recombinant AAV (rAAV) vectors are the most suitable
candidates for virus-based gene therapy because of their broad
tissue tropism, nonpathogenic nature, and low immunogenic-
ity (Deyle, 2009, No. 412; Pillay, 2016, No. 801). In our study,
we adapted a dual AAV vector system packaging SpCas9 and
SpGuide.13 In the SpGuide vector the Syn promoter was
replaced with ICAM2 promoter (pICAM2), an endothelial-
specific promoter (Fig. 1A), for driving green fluorescence
protein (GFP) expression; Mecp2 promoter was substituted for
pICAM2 for driving SpCas9 expression in the AAV-SpCas920,30
(Fig. 1B). Subsequently, the dual AAV vectors of AAV-SpGuide
with the lacZ-sgRNA or K7-sgRNA and AAV-SpCas9 were used
to produce rAAV5 in the 293T cells because rAAV5 has been
shown to infect endothelial cells (ECs) at high efficiency.31
To demonstrate whether the ICAM2 promoter could drive
protein expression specifically in vascular ECs, we infected
ARPE-19 cells, a spontaneously immortalized cell line of retinal
pigment epithelial cells, and HRECs with rAAV5-pICAM2-GFP
and rAAV5-pICAM2-SpCas9, respectively. As shown in Figures
1C and 1D, expression of GFP and SpCas9 was detected in
HRECs, but not in ARPE-19 cells, but the cytomegalovirus
(CMV) promoter-driven GFP expression in rAAV5-CMV-GFP
was able to be detected in both ARPE-19 cells and HRECs (Fig.
1E). Taken together, these results demonstrated that the dual
AAV-CRISPR/Cas9 system is able to specifically target genomic
loci of vascular ECs.
AAV5-CRISPR/Cas9–Mediated Depletion of VEGFR2
To identify sgRNAs to effectively guide SpCas9 to edit the
genomic VEGFR2 locus, four protospacers were selected from
exon 18 of human VEGFR232 and cloned into the lentiCRISPR
v2 vector by BsmB1. The confirmed lentivectors by DNA
sequencing were used to produce lentiviruses in HEK 293T cells
for infecting PAEC-KDR cells. Western blot analysis showed that
expression of VEGFR2 was reduced approximately 90% in the
PAEC-KDR cells infected by lentiCRSIRP v2-K7-sgRNA and this
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was the most effective sgRNA among the four sgRNAs in
depleting VEGFR2 (Fig. 2). Therefore, the K7-sgRNA and lacZ-
sgRNA were cloned into the SpGuide vector by SapI (Fig. 1A) for
production of rAAV5, respectively; in addition, the vector of
AAV-SpCas9 (Fig. 1B) was also subjected to generation of rAAV5.
To assess the editing efficiency, we infected HRECs by using
rAAV5-SpCas9 with rAAV5-VEGFR2 (K7) or rAAV5-lacZ. Seven
days post infection, the genomic DNA was isolated for PCR.
Sanger DNA sequencing results showed that there were
mutations around the PAM sequence of PCR products from
HRECs transduced with rAAV5-SpCas9 plus –VEGFR2-sgRNA
(K7), but not from those with rAAV5-SpCas9 plus –lacZ-sgRNA
(Fig. 3B), indicating that the K7 sgRNA-guided SpCas9 cleaved
the VEGFR2 locus at the expected site. NGS indicated that
there were approximately 80% indels generated from the loci
around the PAM of K7 sgRNA (Fig. 3C), but we did not find any
indels among the most possible off-target by Sanger DNA
sequencing and NGS; Western blot analysis of the infected cell
lysates demonstrated an 80% decrease in VEGFR2 in the HRECs
infected with the dual rAAV5 of SpCas9/VEGFR2-sgRNA (K7),
compared with those transduced with SpCas9/lacZ-sgRNA
(Fig. 3D). These results demonstrated that the AAV-CRISRP/
Cas9 system with K7-sgRNA efficiently induced mutations
FIGURE 1. Establishment of dual AAV vectors for delivering CRISPR/Cas9 and confirmation of pICAM2 specificity in vascular ECs. (A) Schematic of
AAV-U6-sgRNA-pICAM2-GFP. The hSyn promoter in AAV-SpGuide was substituted by pICAM2 by XbaI/SalI. A protospacer sequence could be cloned
into this vector by SapI for synthesizing sgRNA. (B) Schematic of AAV-pICAM2-SpCas9. The ICAM2 promoter was used to replace the Mecp2
promoter in the AAV-SpCas9 by using Xbal/AgeI for driving expression of SpCas9 specifically in vascular ECs. (C–E) ARPE-19 cells and HRECs were
grown to 50% confluence in 48-well plates, AAV5-pICAM2-GFP, AAV5-pICAM2-SpCas9, or AAV5-CMV-GFP (3.753 1012 GC/mL) were added into the
wells (2 lL/well). Two days later the cells were photographed by fluorescence microscopy (C, E), and the lysates of the cells transduced by AAV5-
pICAM2-SpCas9 were subjected to Western blot analysis with antibodies against Cas9 and b-actin (E). These experiments were repeated at least
three times.
FIGURE 2. Selection of an effective sgRNA. Western blot analysis of
VEGFR2 expression in the CRISPR/Cas9-engineered PAE-KDR cells,
using indicated antibodies. lacZ-sgRNA served as a negative control
sgRNA. Lanes of LacZ, K7, K8, K9, and K10 denote the protein samples
from PAE-KDR cells, which were transduced by SpCas9 together with
lacZ-, K7-, K8-, K9-, or K10-sgRNAs. ‘‘Fold’’ was calculated by first
normalizing to the level of b-actin and then calculating the ratio of the
K7, K8, K9, and K10 over the LacZ lane, respectively. Data of bar
graphs are representative of three independent experiments and the
error bars are standard derivation (SD).
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within the VEGFR2 locus and subsequent protein depletion in
HRECs.
Editing VEGFR2 Using CRISPR/Cas9 Blocked VEGF-
Induced Activation of Akt
VEGF binding to VEGFR2 can trigger the phosphatidylinositol-
4,5-bisphosphate 3-kinase (PI3K)/Akt signaling pathway.33 Akt,
also known as protein kinase B, is a serine/threonine kinase
that plays a key role in multiple cellular responses including
proliferation and migration, which are all intrinsic to angio-
genesis.34,35 To evaluate whether AAV-CRISPR/Cas9–mediated
depletion of VEGFR2 prevented VEGF-induced Akt, we
cultured HRECs to approximately 80% confluence in the
growth factor–free medium and then treated them with VEGF
for 30 minutes. Western blot analysis showed that VEGF-
induced activation of Akt was nearly completely blocked by
AAV5-CRISPR/Cas9–mediated depletion of VEGFR2 (Fig. 4).
These data indicate that the AAV5-CRISPR/Cas9–mediated
FIGURE 3. AAV5-CRISPR/Cas9–mediated depletion of VEGFR2. (A) Schematic of a target DNA sequence (K7) preceding a 50-NGG PAM sequence at
exon 18 in the genomic VEGFR2 locus (NC_000071.6), which was selected for generating sgRNA. The red triangle points to an expected cleavage
site of SpCas9 at the human genomic VEGFR2 locus. (B, C) Purified PCR products from the CRISPR/Cas9-engineered HRECs were subjected to
Sanger DNA sequencing. The DNA sequencing results, indicated by lacZ-sgRNA and K7-sgRNA, were derived from the HRECs transduced by SpCas9
together with lacZ-sgRNA or K7-sgRNA. The PAMs are indicated above a thick blue line and the expected cleavage site of SpCas9 is indicated by a
red triangle. (D) Western blot analysis of VEGFR2 expression in the AAV-CRISPR/Cas9–edited HRECs, using indicated antibodies. lacZ-sgRNA served
as a negative sgRNA control. ‘‘Fold’’ was calculated by first normalizing to the level of b-actin and then calculating the ratio of the VEGFR2 over the
LacZ lane. This is representative of three independent experiments and error bars are SD.
FIGURE 4. AAV-CRISPR/Cas9–mediated depletion of VEGFR2 prevents VEGF-induced activation of Akt. The HRECs transduced with the dual AAV
vectors, as described in Figure 3, in growth factor–free medium overnight in wells of a 24-well plate, were treated with VEGF (20 ng/mL) for 30
minutes. The cell lysates were then subjected to Western blot by using the indicated antibodies. The lanes of LacZ and VEGFR2 represent the cell
lysates from HRECs transduced by SpCas9 together with lacZ-sgRNA or VEGFR2-sgRNA. ‘‘Fold’’ was calculated by first normalizing to the level of b-
actin or Akt and then calculating the ratio of the VEGFR2 and other lanes over the LacZ lane. Data of bar graphs are representative of three
independent experiments.
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depletion of VEGFR2 has potential to block VEGF-induced
cellular responses via blocking VEGF-induced activation of Akt.
Editing VEGFR2 Using CRISPR/Cas9 Prevented
VEGF-Induced Proliferation and Migration
VEGF-induced autophosphorylation of VEGFR2 stimulates
cellular responses including cell proliferation and migra-
tion.35–37 To examine VEGF-induced proliferation of HRECs
that had been transduced by SpCas9 together with VEGFR2-
sgRNA or lacZ-sgRNA, these HRECs were deprived of the
growth factors overnight and then treated with VEGF (20 ng/
mL) for 48 hours.22,38 As expected, VEGF stimulated prolifer-
ation of HRECs transduced by SpCas9 with lacZ-sgRNA but
failed to induce the proliferation of HRECs transduced by
SpCas9 with VEGFR2-sgRNA (Fig. 5A).
Migration is one of the important cellular events in the
process of angiogenesis,39 so we investigated whether AAV-
CRISPR/Cas9–mediated depletion of VEGFR2 prevented VEGF-
induced migration of HRECs. HRECs infected with the dual
AAV vectors of AAV5-SpCas9 plus VEGFR2-sgRNA (K7) or lacZ-
sgRNA were examined in a scratch wound-healing assay. As
shown in Figure 5B, whereas VEGF induced migration of
HRECs transduced with SpCas9 plus lacZ-sgRNA, it failed to
stimulate the migration of HRECs with SpCas9 plus VEGFR2-
sgRNA (K7), indicating that editing genomic VEGFR2, using
the dual AAV system, is able to block VEGF-induced endothelial
cell proliferation and migration.
AAV-CRISPR/Cas9–Mediated Depletion of VEGFR2
Blocked VEGF-Induced Tube Formation
To evaluate whether AAV-CRISPR/Cas9–mediated depletion of
VEGFR2 prevented VEGF-induced tube formation, an in vitro
model of endothelial morphogenesis,19,29,38,40,41 HRECs infect-
ed with the dual AAV system of AAV-SpCas9 with VEGFR2-
sgRNA (K7) or lacZ-sgRNA were used in a collagen-based tube
formation assay. As shown in Figure 6, VEGF stimulated tube
formation in the HRECs transduced by SpCas9 with lacZ-
sgRNA, but it did not induce this reaction in those that were
transduced by VEGFR2-sgRNA (K7)/SpCas9. These results
suggest that editing genomic VEGFR2 with VEGFR2-sgRNA
(K7)/SpCas9 is a potentially powerful therapeutic approach to
the treatment of abnormal angiogenesis.
DISCUSSION
Herein we reported that AAV-CRISPR/Cas9–mediated depletion
of VEGFR2 in HRECs blocked VEGF-stimulated Akt activation
and cellular responses intrinsic to angiogenesis. Angiogenesis
plays a significant role in a number of pathologic conditions,
such as PDR and wet AMD.42 VEGFR2-sgRNA (K7) was used in
this study to efficiently guide SpCas9 to cleave the double DNA
strands in exon 18 of the human genomic VEGFR2, leading to a
nonhomologous end joining (NHEJ) repair and resulting in
indels in the VEGFR2 locus and subsequent depletion of
FIGURE 5. AAV-CRISPR/Cas9–mediated depletion of VEGFR2 prevented VEGF-induced proliferation and migration. (A) HRECs transduced with the
dual AAV vectors, as described in Figure 3, were plated in wells of 48-well plates (15,000 cells per well). After cell attachment, they were switched
to growth factor–free medium for 7 hours and VEGF (20 ng/mL) was added into the cells as indicated. After 48 hours, the cells were trypsin
detached and then counted in a hemocytometer under a light microscope. (B) HRECs transduced with the dual AAV vectors (described in Fig. 3) and
grown to near confluence in a 48-well plate were deprived of growth factors for 7 hours, and then scratched with a sterile 200-lL pipette tip. After
washing twice with PBS, the cells were treated with VEGF (20 ng/mL). After 16 hours, the scratched area was photographed, the boundaries of
scratches were outlined with the lines, and the scratched areas were analyzed with ImageJ software. Each bar graph indicates mean 6 SD of three
independent experiments. ‘‘*’’ denotes a significant difference in results between the two compared groups. P < 0.05 using an unpaired t-test. One
representative experiment was shown below.
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VEGFR2 expression in HRECs. Not all sgRNAs designed by
using the online tool would be expected to have the same
efficiency in guiding SpCas9,43 so we designed four sgRNAs
from exon 18 of the human genomic VEGFR; the K7-sgRNA
was the most efficient among the four sgRNAs. Previously, we
have reported that an sgRNA generated from a protospacer in
exon 3 of the human genomic VEGFR2 also efficiently guides
SpCas9 to cleave its target around the PAM with subsequent
depletion of VEGFR2 in lentivirally infected HRECs.19 In this
report, we extended the study by using the dual AAV5-CRISPR/
Cas9–infected HRECs and explored a potential opportunity
with this sgRNA to prevent angiogenesis-related diseases.
AAV vectors have been used in clinical trials for gene
transfer in liver (Wang, 2000, No. 692) and to retina for Leber’s
congenital amaurosis.44,45 Thus, we adapted the dual AAV
system for delivering CRISPR/Cas9 into HRECs. AAV5 has been
shown to enter the cells via platelet-drived growth factor
receptor (PDGFR),46 but our results indicated that the PDGFRs
are not essential for AAV5 to enter the cells because the cells
engineered without PDGFRs could be transduced by AAV5
(data not shown). In addition, AAV5 has been shown
previously to effectively transduce vascular ECs.47 Our results
showed that rAAV5-VEGFR2-sgRNA (K7)/SpCas9 efficiently
depleted VEGFR2 expression in HRECs, suggesting that this
dual AAV system has potential to be translated into a
therapeutic purpose for pathologic angiogenesis. At present,
anti-VEGF agents (e.g., ranibizumab and aflibercept) are the
standard care for intraocular neovascularization such as PDR
and wet AMD. While these anti-VEGF agents can reduce
angiogenesis and vascular leakage, therapeutic challenges
remain, including the need for chronic treatment and the fact
that a significant number of patients do not respond. Gene
therapy targeting genomic VEGFR2 in vascular ECs, using AAV-
CRIPSR/Cas9, may provide a potential novel alternative
approach. However, VEGFR2 is essential for survival of
vascular ECs48,49; in addition, it has been shown that
conditional knockout of VEGF in retinal pigment epithelial
cells leads to death of choroid capillaries and to cone
photoreceptor degeneration.50 Furthermore, we have previ-
ously reported that AAV1-mediated CRISPR/Cas9 abrogates
angiogenesis in mouse models of oxygen-induced retinopathy
and laser-induced choroidal neovascularization.13 Whether
AAV5-mediated CRISPR/Cas9 could block angiogenesis in vivo
and whether AAV5 is superior to AAV1 for delivering CRISPR/
Cas9 into pathologic angiogenic ECs need further investiga-
tion.
Technologies used for genome editing based on program-
mable nucleases51 such as zinc finger nucleases,52 transcrip-
tion activator–like effector nucleases,53 and CRISPR/Cas9 are
opening up the possibility of achieving therapeutic genome
editing in diseased cells and tissues.54 CRISPR/Cas9 technol-
ogy enables especially precise genome editing by introducing
DNA double-strand breaks at specific genomic loci with
subsequent protein depletion. However, genetic modifications
are permanent, and deleterious off-target mutations could
reduce cellular integrity, leading to functional impairment or
creating cells with oncogenic potential.54,55 Rational engineer-
ing of SpCas9 would be expected to lead to improvement.
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